The four leading international health and humanitarian organizations announced the establishment of a global Ebola vaccine stockpile to ensure outbreak response. The effort to establish…
The VSV-EBOPLUS scientist Helder Nakaya has been recognized as one of the Highly Cited Researchers 2020 and as a true pioneer in the field of…
Due to the COVID-19 crisis, the VSV-EBOPLUS Project meeting 2020 was held as online meeting on 21st and 22nd September 2020. Representatives of each Institution…
Due to the COVID-19 crisis, the planned VSV-EBOPLUS Project meeting in Camogli (Genova, Italy) has been canceled. Therefore, a virtual project meeting is scheduled on…
The U.S. Food and Drug Administration announced today the approval of Ervebo, the first FDA-approved vaccine for the prevention of Ebola virus disease (EVD), caused…
The World Health Organization (WHO) today prequalified an Ebola vaccine for the first time, a critical step that will help speed up its licensing, access…
EMA’s human medicines committee (CHMP) has recommended granting a conditional marketing authorisation in the European Union for Ervebo (rVSVΔG-ZEBOV-GP), the first vaccine for active immunisation…
Today, the European Commission adopted the decision granting marketing authorisation to the company Merck Sharp & Dohme B.V. for a vaccine against Ebola. This vaccine,…
https://www.repubblica.it/salute/prevenzione/2017/11/21/news/tutti_i_vaccini_del_terzo_millennio-181599792/ “Tutti i vaccini del terzo millennio” on the Italian newspaper La Repubblica Salute, 14 November 2017
SIENA – Lotta all’Ebola: al via un grande progetto di ricerca sullo studio della risposta al vaccino VSV-ZEBOVL’Università di Siena in prima lineaParte da Siena un nuovo…